An Eight-Week, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Tolerability of One Fixed 100 mg Dose of Saredutant in Patients With Major Depressive Disorder.
Phase of Trial: Phase III
Latest Information Update: 02 Jun 2011
At a glance
- Drugs Saredutant (Primary)
- Indications Major depressive disorder
- Focus Registrational; Therapeutic Use
- Sponsors Sanofi
- 22 Dec 2008 Actual end date (Dec 2006) added as reported by ClinicalTrials.gov.
- 22 Dec 2008 Actual number of patients (467) added as reported by ClinicalTrials.gov.
- 31 Aug 2006 New trial record.